Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4

NCT00526448 is registered in ClinicalTrials.gov with Hospital Carlos III, Madrid as lead sponsor.

NCT NCT00526448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4
Lead sponsor
Hospital Carlos III, Madrid
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2007
Completion date
February 28, 2010
Enrollment
384 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c